Evidation Health and Eli Lilly Study Uses Apple Devices and Apps to Predict Cognitive Impairment
The results of the trial set the groundwork for future research that may be able to help identify people with neurodegenerative conditions.
Aug 11, 2019 | By Kevin Truong | MedCity News
The growing ubiquity of powerful sensor technology in consumer devices have led to the development of tools meant to predict potential health risks like heart attacks and epileptic seizures. Increasingly, these devices may also be of use in the case of neurodegenerative conditions.
Early results from a study conducted by Evidation Health, Eli Lilly and Apple have shown the ability to detect cognitive decline and mild Alzheimer’s disease using a combination of Apple wearables, mobile devices, digital apps and sleep sensors. Devices used included the iPhone, Apple Watch, iPad and the Beddit sleep monitoring device.
The early data also showed the ability to differentiate between people with mild cognitive impairment and mild Alzheimer’s disease.
The study, which included 113 individuals between the ages of 60 and 75, examined data acquired from a range of different sources including passively collected sensor data, surveys about mood and energy and assessments through a digital app developed by the researchers which had participants perform reading, typing and psychomotor tasks.
Through this data, researchers were able to link certain behaviors or markers that were indicative of cognitive impairment including typing speed, when individuals took their first daily step and the total number of messages received by participants.
The researchers also identified poor survey compliance and a reliance on “helper apps” like Siri and the Clock app as signifiers of cognitive decline.
“Over the past few years, we’ve seen how data and insights derived from wearables and mobile consumer devices have enabled people living with health conditions, along with their clinicians, to better monitor their health,” Evidation Health data scientist Nikki Marinsek in a statement.
“We know that insights from smart devices and digital applications can lead to improved health outcomes, but we don’t yet know how those resources can be used to identify and accelerate diagnoses. The results of the trial set the groundwork for future research that may be able to help identify people with neurodegenerative conditions earlier than ever before.”
Ultimately, the researchers hope to be able to use the learnings gleaned from the research to develop early screening tools for those at high risk of cognitive decline or detect dementia and Alzheimer’s disease earlier using common devices.
Erika Augustine MD, MS
Tauna Batiste MS
Alison Bateman-House PhD, MPH, MA
Sharon Begley BA
Derek Bowen BS
PJ Brooks PhD
Program Director, Office of Rare Diseases Research, National Center for Advancing Translational Sciences, NIH
Wilson Bryan MD
Mona Chitre PharmD
Danielle Edwards BA
Emily Farkas PA-C
Tanya Fischer MD, PhD
Jayne Gershkowitz BA
Martin Graham PhD
David Jacoby MD, PhD
Karl Kieburtz MD, MPH
Jinkuk Kim PhD
Nikki Marinsek PhD
Rachel McMinn PhD
Elissa Orlando MPA
Sean Nicholson PhD
Traci Schilling MD
Benjamin Schlatka MBA
Scott Steele PhD
Marshall Summar MD
Holly Tabor PhD
Nancy Yu BS
Dina Zand MD